Rouen

• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Recruiting
  2022-502642-27-00 9 2020-11-26 RElapse in previously irradiated Prostate bed
• Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma. Recruiting
  2024-515384-62-00 5 2020-10-09 Soft Tissue Sarcoma
• Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or deno … Recruiting
  2024-513248-27-00 5 2020-07-20 Patients, men or women over 18 old, with inoperable vertebral bone met
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of pa … Recruiting
  2023-510567-35-00 4 2020-06-10 Advanced / metastatic cancers
• Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine ad … Recruiting
  2024-514603-34-00 5 2020-03-02 intermediate-risk differentiated thyroid cancer patients
• LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MA … Recruiting
  2024-514362-39-00 4 2019-12-05 Diabetic macular oedema
• PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting
  2024-512173-27-00 5 2019-03-21 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment wi
• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended recruitment
  2025-521302-17-00 10 2026-05-26 Hihg risk of cholangiocarcinoma intra hépatic resectable
• A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended recruitment
  2024-515773-99-00 4 2025-05-26 Pulmonary Hypertension
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• Evaluation of TNF-alpha antagonists (infliximab) withdrawal in sarcoidosis Ended recruitment
  2024-516965-35-00 5 2024-10-28 Immune system disorders
• STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem … Ended recruitment
  2023-504176-25-00 9 2024-08-08 Acute Myeloid Leukemia
• PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO Ended recruitment
  2024-513718-37-00 4 2024-08-01 IGHV unmutated patients with high-risk stage A CLL features.
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme … Ended recruitment
  2022-501372-25-00 4 2024-01-10 Patients aged 18 years and older with relapsed or refractory FLT3 muta
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma

Showing 97–120 of 173 trials